 POTOMAC, MD--BUSINESS WIRE-- AD--India Globalization Capital, Inc. IGC or the Company NYSE American: IGC announced that it is enrolling participants suffering from mild to severe dementia due to Alzheimers disease for its Phase 1 clinical trial. Our subsidiary, IGC Pharma, LLC, received approval from an Institutional Review Board IRB as previously disclosed, engaged a Principal Investigator and a study site, and began enrolling participants for a Phase 1 trial on its Investigational D 